SLU-PP-915: limits of adverse-event evidence
Billon and colleagues studied SLU-PP-915 in mice using oral and intraperitoneal administration. The inspected abstract describes endurance and molecular measurements, rather than clinical adverse-event frequencies. [1]
This abstract cannot establish adverse reactions or safety in humans or for a particular reagent batch. Findings about SLU-PP-332 should not automatically be transferred to the distinct SLU-PP-915 molecule. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Clinical adverse-event frequencies | Mice, oral and intraperitoneal administration | The abstract describes endurance and molecular measurements rather than clinical adverse-event frequencies; findings about SLU-PP-332 do not transfer to this distinct molecule | [1] |
References
- Billon C et al. (2026). An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity https://doi.org/10.1016/j.jpet.2025.103787.